
News|Articles|October 1, 2004
Rofecoxib voluntarily withdrawn from market due to cardiovascular risk
Rofecoxib voluntarily withdrawn from market due to cardiovascular risk
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Rural health is ailing. Is $50 billion enough to heal it?
2
GLP-1 medications are linked to hair loss in Type 2 diabetes
3
FDA clears Mimrylo, a first-in-class therapy for polycythemia vera
4
Recombinant shingles vaccine linked to lower cardiovascular disease risk
5























